TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Brief Summary: The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.


Options:
A: Arm Label: sarpogrelate 300 mg per day; Type: EXPERIMENTAL; Interventions: Drug: sarpogrelate | Arm Label: No sarpogrelate medication; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: sarpogrelate; Assigned to Arm(s): sarpogrelate 300 mg per day
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: No aspirin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: No aspirin; Assigned to Arm(s): 2
C: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel, Drug: Commercially-available Aspirin | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel, Drug: Commercially-available Aspirin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Commercially-available Aspirin; Assigned to Arm(s): Clopidogrel, Prasugrel
D: Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients.
Brief Summary: SPECIFIC AIMS

* Assess risk factors for nausea and vomiting in c-section patients undergoing regional anesthesia
* Quantify the incidence of nausea and vomiting intraoperatively and postoperatively in the ginger and placebo groups.
* Quantify post-operative analgesia and pruritus in the ginger and placebo groups
* Quantify patient satisfaction of the ginger and placebo groups
* Assess patient expectation of ginger on post-op day three


Options:
A: Arm Label: Metoclopramide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide | Arm Label: Phenylephrine infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Phenylephrine infusion | Arm Label: Combination Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination Group | Intervention Type: DRUG; Name: Metoclopramide; Assigned to Arm(s): Metoclopramide | Intervention Type: DRUG; Name: Phenylephrine infusion; Assigned to Arm(s): Phenylephrine infusion | Intervention Type: DRUG; Name: Combination Group; Assigned to Arm(s): Combination Group
B: Arm Label: Exteriorization group; Type: OTHER; Interventions: Procedure: Repair of uterine incision, Procedure: Exteriorization of the uterus | Arm Label: Non exteriorization group; Type: OTHER; Interventions: Procedure: Repair of uterine incision, Procedure: Non exteriorization of the uterus | Intervention Type: PROCEDURE; Name: Repair of uterine incision; Assigned to Arm(s): Exteriorization group, Non exteriorization group | Intervention Type: PROCEDURE; Name: Exteriorization of the uterus; Assigned to Arm(s): Exteriorization group | Intervention Type: PROCEDURE; Name: Non exteriorization of the uterus; Assigned to Arm(s): Non exteriorization group
C: Arm Label: Phenylephrine bolus; Type: EXPERIMENTAL; Interventions: Drug: Phenylephrine bolus | Arm Label: Phenylephrine infusion; Type: EXPERIMENTAL; Interventions: Drug: phenylephrine infusion | Intervention Type: DRUG; Name: Phenylephrine bolus; Assigned to Arm(s): Phenylephrine bolus | Intervention Type: DRUG; Name: phenylephrine infusion; Assigned to Arm(s): Phenylephrine infusion
D: Arm Label: Ginger; Type: EXPERIMENTAL; Interventions: Drug: Ginger | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Ginger; Assigned to Arm(s): Ginger | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage in Women With Risk Factors for Uterine Atony
Brief Summary: Objective: to demonstrate that buccal misoprostol administration during cesarean delivery in women with risk factors for uterine atony decreases the need for additional uterotonic medications, uterine atony and postpartum hemorrhage.

Design: randomized, double-blinded, placebo-controlled trial.


Options:
A: Arm Label: Carbetocin; Type: N/A; Interventions: N/A | Arm Label: Oxytocin; Type: N/A; Interventions: N/A
B: Arm Label: Short infusion; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin Short-infusion | Arm Label: Bolus application; Type: OTHER; Interventions: Drug: Carbetocin Bolus application | Intervention Type: DRUG; Name: Carbetocin Short-infusion; Assigned to Arm(s): Short infusion | Intervention Type: DRUG; Name: Carbetocin Bolus application; Assigned to Arm(s): Bolus application
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Folic Acid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic Acid
D: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Carbetocin; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage in Women With Risk Factors for Uterine Atony
Brief Summary: Objective: to demonstrate that buccal misoprostol administration during cesarean delivery in women with risk factors for uterine atony decreases the need for additional uterotonic medications, uterine atony and postpartum hemorrhage.

Design: randomized, double-blinded, placebo-controlled trial.


Options:
A: Arm Label: Carbetocin; Type: N/A; Interventions: N/A | Arm Label: Oxytocin; Type: N/A; Interventions: N/A
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Folic Acid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic Acid
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin infusion | Intervention Type: DRUG; Name: Oxytocin infusion; Assigned to Arm(s): A
D: Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-Blinded Study to Evaluate the Efficacy of Intravenous Dexamethasone for Nausea Prophylaxis Prior to Duramorph and Bupivacaine Spinal Anesthesia for Scheduled Cesarean Section
Brief Summary: Patients who present for scheduled (non-emergent) cesarean section will be given either intravenous dexamethasone or placebo prior to receiving a duramorph containing spinal anesthetic. The investigators will then compare the incidence of nausea and vomiting and the use of rescue anti-nausea medications in both groups. Our hypothesis is that patients receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section will have a significantly lower incidence and severity of PONV at 0, 1, 3, 6, and 24 hours following surgery.


Options:
A: Arm Label: morphine group; Type: ACTIVE_COMPARATOR; Interventions: Other: spinal anesthesia with intrathecal morphine | Arm Label: TAP group; Type: EXPERIMENTAL; Interventions: Other: TAP-block with ropivacaine and clonidine | Intervention Type: OTHER; Name: spinal anesthesia with intrathecal morphine; Assigned to Arm(s): morphine group | Intervention Type: OTHER; Name: TAP-block with ropivacaine and clonidine; Assigned to Arm(s): TAP group
B: Arm Label: Phenylephrine bolus; Type: EXPERIMENTAL; Interventions: Drug: Phenylephrine bolus | Arm Label: Phenylephrine infusion; Type: EXPERIMENTAL; Interventions: Drug: phenylephrine infusion | Intervention Type: DRUG; Name: Phenylephrine bolus; Assigned to Arm(s): Phenylephrine bolus | Intervention Type: DRUG; Name: phenylephrine infusion; Assigned to Arm(s): Phenylephrine infusion
C: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Metoclopramide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide | Arm Label: Phenylephrine infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Phenylephrine infusion | Arm Label: Combination Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination Group | Intervention Type: DRUG; Name: Metoclopramide; Assigned to Arm(s): Metoclopramide | Intervention Type: DRUG; Name: Phenylephrine infusion; Assigned to Arm(s): Phenylephrine infusion | Intervention Type: DRUG; Name: Combination Group; Assigned to Arm(s): Combination Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate
Brief Summary: The purpose of this study is to compare two different medicines to treat babies with opiate withdrawal. The treatment medicines are morphine, which is an opiate, and clonidine, a non-opiate. Morphine is a narcotic medicine, with is included in most pain killers. Clonidine is another drug, but is different from morphine. It is also used for babies, and even adults for withdrawal symptoms. Both drugs are effective, but the purpose of this study is to see if one may be better than the other.


Options:
A: Arm Label: SVS vs Control; Type: EXPERIMENTAL; Interventions: Device: Stochastic Vibrotactile Stimulation (SVS), Other: Control | Intervention Type: DEVICE; Name: Stochastic Vibrotactile Stimulation (SVS); Assigned to Arm(s): SVS vs Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): SVS vs Control
B: Arm Label: Song of Kin; Type: EXPERIMENTAL; Interventions: Behavioral: Song of Kin | Arm Label: Gato box; Type: EXPERIMENTAL; Interventions: Other: Gato box | Arm Label: Ocean disc; Type: EXPERIMENTAL; Interventions: Other: Ocean disc | Arm Label: Contingent singing; Type: EXPERIMENTAL; Interventions: Other: Contingent singing | Arm Label: Tonal Vocal holding; Type: EXPERIMENTAL; Interventions: Other: Tonal Vocal holding | Arm Label: Muted shaker; Type: EXPERIMENTAL; Interventions: Other: Muted shaker | Intervention Type: BEHAVIORAL; Name: Song of Kin; Assigned to Arm(s): Song of Kin | Intervention Type: OTHER; Name: Gato box; Assigned to Arm(s): Gato box | Intervention Type: OTHER; Name: Ocean disc; Assigned to Arm(s): Ocean disc | Intervention Type: OTHER; Name: Contingent singing; Assigned to Arm(s): Contingent singing | Intervention Type: OTHER; Name: Tonal Vocal holding; Assigned to Arm(s): Tonal Vocal holding | Intervention Type: OTHER; Name: Muted shaker; Assigned to Arm(s): Muted shaker
C: Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Clonidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clonidine | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): Clonidine
D: Arm Label: Oral morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine Sulfate | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Morphine Sulfate; Assigned to Arm(s): Oral morphine sulfate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate
Brief Summary: The purpose of this study is to compare two different medicines to treat babies with opiate withdrawal. The treatment medicines are morphine, which is an opiate, and clonidine, a non-opiate. Morphine is a narcotic medicine, with is included in most pain killers. Clonidine is another drug, but is different from morphine. It is also used for babies, and even adults for withdrawal symptoms. Both drugs are effective, but the purpose of this study is to see if one may be better than the other.


Options:
A: Arm Label: Oral morphine solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral morphine solution | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine | Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Oral morphine solution; Assigned to Arm(s): Oral morphine solution
B: Arm Label: methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): methadone | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): morphine
C: Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Clonidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clonidine | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): Clonidine
D: Arm Label: sublingual buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: sublingual buprenorphine | Arm Label: oral morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral morphine | Intervention Type: DRUG; Name: sublingual buprenorphine; Assigned to Arm(s): sublingual buprenorphine | Intervention Type: DRUG; Name: oral morphine; Assigned to Arm(s): oral morphine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential Mechanisms
Brief Summary: The proposed mechanistic formula feeding study sets out to identify the mechanism(s) by which an extensively hydrolyzed casein formula is able to protect children at risk for type 1 diabetes (T1D) from beta-cell autoimmunity.


Options:
A: Arm Label: extensively hydrolyzed casein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: dietary intervention | Arm Label: cow's milk based infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: dietary intervention | Intervention Type: DIETARY_SUPPLEMENT; Name: dietary intervention; Assigned to Arm(s): cow's milk based infant formula, extensively hydrolyzed casein formula
B: Arm Label: A highly hydrolyzed casein formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: A highly hydrolyzed formula | Arm Label: A conventiona cow's milk based formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: A regular cow's milk based formula | Intervention Type: DIETARY_SUPPLEMENT; Name: A highly hydrolyzed formula; Assigned to Arm(s): A highly hydrolyzed casein formula | Intervention Type: DIETARY_SUPPLEMENT; Name: A regular cow's milk based formula; Assigned to Arm(s): A conventiona cow's milk based formula
C: Arm Label: Hydrolysed infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Hydrolysed infant formula | Arm Label: Nonhydrolysed infant formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nonhydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydrolysed infant formula; Assigned to Arm(s): Hydrolysed infant formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Nonhydrolysed infant formula; Assigned to Arm(s): Nonhydrolysed infant formula
D: Arm Label: Group EEEEEEE; Type: ACTIVE_COMPARATOR; Interventions: Other: Enfamil, milk-based formula | Arm Label: Group ENEEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EENEEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group EEENEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group ENNNEEE; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Arm Label: Group NNNNNNN; Type: EXPERIMENTAL; Interventions: Other: Nutramigen (Flavor and Type of Infant Formula) | Intervention Type: OTHER; Name: Nutramigen (Flavor and Type of Infant Formula); Assigned to Arm(s): Group EEENEEE, Group EENEEEE, Group ENEEEEE, Group ENNNEEE, Group NNNNNNN | Intervention Type: OTHER; Name: Enfamil, milk-based formula; Assigned to Arm(s): Group EEEEEEE

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential Mechanisms
Brief Summary: The proposed mechanistic formula feeding study sets out to identify the mechanism(s) by which an extensively hydrolyzed casein formula is able to protect children at risk for type 1 diabetes (T1D) from beta-cell autoimmunity.


Options:
A: Arm Label: extensively hydrolyzed casein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: dietary intervention | Arm Label: cow's milk based infant formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: dietary intervention | Intervention Type: DIETARY_SUPPLEMENT; Name: dietary intervention; Assigned to Arm(s): cow's milk based infant formula, extensively hydrolyzed casein formula
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Enfamil LIPIL with iron | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Good Start Supreme with DHA and ARA | Intervention Type: OTHER; Name: Enfamil LIPIL with iron; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Good Start Supreme with DHA and ARA; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: infant formula | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: infant formula | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: infant formula | Intervention Type: OTHER; Name: infant formula; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Cow's milk formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Bovine insulin-free whey based formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Arm Label: Whey-based hydrolysed formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cow's milk formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk formula; Assigned to Arm(s): Bovine insulin-free whey based formula, Cow's milk formula, Whey-based hydrolysed formula

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Attempt to Optimize the Results of Liver Transplantation With Administration of Probiotics.
Brief Summary: The aim of this study was to evaluate the impact of the administration of probiotics on outcomes of patients qualified for liver transplantation, both in the pre-transplant period and in the early postoperative period.


Options:
A: Arm Label: I; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: Probiotic Supplement | Intervention Type: DRUG; Name: Probiotic Supplement; Assigned to Arm(s): II | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): I
B: Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: CONTROL | Arm Label: SYNBIOTIC; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SYNBIOTIC | Intervention Type: DIETARY_SUPPLEMENT; Name: CONTROL; Assigned to Arm(s): CONTROL | Intervention Type: DIETARY_SUPPLEMENT; Name: SYNBIOTIC; Assigned to Arm(s): SYNBIOTIC
C: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotic

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Attempt to Optimize the Results of Liver Transplantation With Administration of Probiotics.
Brief Summary: The aim of this study was to evaluate the impact of the administration of probiotics on outcomes of patients qualified for liver transplantation, both in the pre-transplant period and in the early postoperative period.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Resistant Starch; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Resistant starch | Arm Label: Exercise & Resistant Starch; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Resistant starch, Behavioral: Exercise | Arm Label: Starch; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Starch | Intervention Type: DIETARY_SUPPLEMENT; Name: Resistant starch; Assigned to Arm(s): Exercise & Resistant Starch, Resistant Starch | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise, Exercise & Resistant Starch | Intervention Type: BEHAVIORAL; Name: Starch; Assigned to Arm(s): Starch
B: Arm Label: Arabinoxylan-oligosaccharides; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Arabinoxylan-oligosaccharides | Arm Label: Maltodextrine; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrine | Intervention Type: DIETARY_SUPPLEMENT; Name: Arabinoxylan-oligosaccharides; Assigned to Arm(s): Arabinoxylan-oligosaccharides | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrine; Assigned to Arm(s): Maltodextrine
C: Arm Label: Synbiotic Arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg; Assigned to Arm(s): Synbiotic Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm
D: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotic

Answer: D